FASN, CPTAC-369 - CPTAC Assay Portal (original) (raw)

Please include the following statement when referencing the CPTAC Assay Portal

We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Protein Sequence hover to view complete sequence

10 20 30 40 50
MEEVVIAGMS GKLPESENLQ EFWDNLIGGV DMVTDDDRRW KAGLYGLPRR
60 70 80 90 100
SGKLKDLSRF DASFFGVHPK QAHTMDPQLR LLLEVTYEAI VDGGINPDSL
110 120 130 140 150
RGTHTGVWVG VSGSETSEAL SRDPETLVGY SMVGCQRAMM ANRLSFFFDF
160 170 180 190 200
RGPSIALDTA CSSSLMALQN AYQAIHSGQC PAAIVGGINV LLKPNTSVQF
210 220 230 240 250
LRLGMLSPEG TCKAFDTAGN GYCRSEGVVA VLLTKKSLAR RVYATILNAG
260 270 280 290 300
TNTDGFKEQG VTFPSGDIQE QLIRSLYQSA GVAPESFEYI EAHGTGTKVG
310 320 330 340 350
DPQELNGITR ALCATRQEPL LIGSTKSNMG HPEPASGLAA LAKVLLSLEH
360 370 380 390 400
GLWAPNLHFH SPNPEIPALL DGRLQVVDQP LPVRGGNVGI NSFGFGGSNV
410 420 430 440 450
HIILRPNTQP PPAPAPHATL PRLLRASGRT PEAVQKLLEQ GLRHSQDLAF
460 470 480 490 500
LSMLNDIAAV PATAMPFRGY AVLGGERGGP EVQQVPAGER PLWFICSGMG
510 520 530 540 550
TQWRGMGLSL MRLDRFRDSI LRSDEAVKPF GLKVSQLLLS TDESTFDDIV
560 570 580 590 600
HSFVSLTAIQ IGLIDLLSCM GLRPDGIVGH SLGEVACGYA DGCLSQEEAV
610 620 630 640 650
LAAYWRGQCI KEAHLPPGAM AAVGLSWEEC KQRCPPGVVP ACHNSKDTVT
660 670 680 690 700
ISGPQAPVFE FVEQLRKEGV FAKEVRTGGM AFHSYFMEAI APPLLQELKK
710 720 730 740 750
VIREPKPRSA RWLSTSIPEA QWHSSLARTS SAEYNVNNLV SPVLFQEALW
760 770 780 790 800
HVPEHAVVLE IAPHALLQAV LKRGLKPSCT IIPLMKKDHR DNLEFFLAGI
810 820 830 840 850
GRLHLSGIDA NPNALFPPVE FPAPRGTPLI SPLIKWDHSL AWDVPAAEDF
860 870 880 890 900
PNGSGSPSAA IYNIDTSSES PDHYLVDHTL DGRVLFPATG YLSIVWKTLA
910 920 930 940 950
RALGLGVEQL PVVFEDVVLH QATILPKTGT VSLEVRLLEA SRAFEVSENG
960 970 980 990 1000
NLVVSGKVYQ WDDPDPRLFD HPESPTPNPT EPLFLAQAEV YKELRLRGYD
1010 1020 1030 1040 1050
YGPHFQGILE ASLEGDSGRL LWKDNWVSFM DTMLQMSILG SAKHGLYLPT
1060 1070 1080 1090 1100
RVTAIHIDPA THRQKLYTLQ DKAQVADVVV SRWLRVTVAG GVHISGLHTE
1110 1120 1130 1140 1150
SAPRRQQEQQ VPILEKFCFT PHTEEGCLSE RAALQEELQL CKGLVQALQT
1160 1170 1180 1190 1200
KVTQQGLKMV VPGLDGAQIP RDPSQQELPR LLSAACRLQL NGNLQLELAQ
1210 1220 1230 1240 1250
VLAQERPKLP EDPLLSGLLD SPALKACLDT AVENMPSLKM KVVEVLAGHG
1260 1270 1280 1290 1300
HLYSRIPGLL SPHPLLQLSY TATDRHPQAL EAAQAELQQH DVAQGQWDPA
1310 1320 1330 1340 1350
DPAPSALGSA DLLVCNCAVA ALGDPASALS NMVAALREGG FLLLHTLLRG
1360 1370 1380 1390 1400
HPLGDIVAFL TSTEPQYGQG ILSQDAWESL FSRVSLRLVG LKKSFYGSTL
1410 1420 1430 1440 1450
FLCRRPTPQD SPIFLPVDDT SFRWVESLKG ILADEDSSRP VWLKAINCAT
1460 1470 1480 1490 1500
SGVVGLVNCL RREPGGNRLR CVLLSNLSST SHVPEVDPGS AELQKVLQGD
1510 1520 1530 1540 1550
LVMNVYRDGA WGAFRHFLLE EDKPEEPTAH AFVSTLTRGD LSSIRWVCSS
1560 1570 1580 1590 1600
LRHAQPTCPG AQLCTVYYAS LNFRDIMLAT GKLSPDAIPG KWTSQDSLLG
1610 1620 1630 1640 1650
MEFSGRDASG KRVMGLVPAK GLATSVLLSP DFLWDVPSNW TLEEAASVPV
1660 1670 1680 1690 1700
VYSTAYYALV VRGRVRPGET LLIHSGSGGV GQAAIAIALS LGCRVFTTVG
1710 1720 1730 1740 1750
SAEKRAYLQA RFPQLDSTSF ANSRDTSFEQ HVLWHTGGKG VDLVLNSLAE
1760 1770 1780 1790 1800
EKLQASVRCL ATHGRFLEIG KFDLSQNHPL GMAIFLKNVT FHGVLLDAFF
1810 1820 1830 1840 1850
NESSADWREV WALVQAGIRD GVVRPLKCTV FHGAQVEDAF RYMAQGKHIG
1860 1870 1880 1890 1900
KVVVQVLAEE PEAVLKGAKP KLMSAISKTF CPAHKSYIIA GGLGGFGLEL
1910 1920 1930 1940 1950
AQWLIQRGVQ KLVLTSRSGI RTGYQAKQVR RWRRQGVQVQ VSTSNISSLE
1960 1970 1980 1990 2000
GARGLIAEAA QLGPVGGVFN LAVVLRDGLL ENQTPEFFQD VCKPKYSGTL
2010 2020 2030 2040 2050
NLDRVTREAC PELDYFVVFS SVSCGRGNAG QSNYGFANSA MERICEKRRH
2060 2070 2080 2090 2100
EGLPGLAVQW GAIGDVGILV ETMSTNDTIV SGTLPQRMAS CLEVLDLFLN
2110 2120 2130 2140 2150
QPHMVLSSFV LAEKAAAYRD RDSQRDLVEA VAHILGIRDL AAVNLDSSLA
2160 2170 2180 2190 2200
DLGLDSLMSV EVRQTLEREL NLVLSVREVR QLTLRKLQEL SSKADEASEL
2210 2220 2230 2240 2250
ACPTPKEDGL AQQQTQLNLR SLLVNPEGPT LMRLNSVQSS ERPLFLVHPI
2260 2270 2280 2290 2300
EGSTTVFHSL ASRLSIPTYG LQCTRAAPLD SIHSLAAYYI DCIRQVQPEG
2310 2320 2330 2340 2350
PYRVAGYSYG ACVAFEMCSQ LQAQQSPAPT HNSLFLFDGS PTYVLAYTQS
2360 2370 2380 2390 2400
YRAKLTPGCE AEAETEAICF FVQQFTDMEH NRVLEALLPL KGLEERVAAA
2410 2420 2430 2440 2450
VDLIIKSHQG LDRQELSFAA RSFYYKLRAA EQYTPKAKYH GNVMLLRAKT
2460 2470 2480 2490 2500
GGAYGEDLGA DYNLSQVCDG KVSVHVIEGD HRTLLEGSGL ESIISIIHSS
2510 2511
LAEPRVSVRE G

Data source: UniProt

Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node

to view detailed assay information below

All other points link out to UniProt

Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for CPTAC-371 Collapse assay details

Data source: Panorama

Official Gene Symbol

FASN

Peptide Sequence

DNLEFFLAGIGR

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

791

Peptide End

802

CPTAC ID

CPTAC-371

Peptide Molecular Mass

1,350.6932

Species

Homo sapiens (Human)

Assay Type

Direct MRM

Matrix

cell line lysate pool

Submitting Laboratory

Broad Institute and FHCRC

Submitting Lab PI

Steve Carr

Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253

Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.

Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

5500 QTRAP (ABSCIEX)

Internal Standard

peptide

Peptide Standard Purity

>95%

Peptide Standard Label Type

13C,15N

LC

nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)

Column Packing

ChromXP C18-CL, 3 um, 120A

Column Dimensions

150 x 0.075 mm

Flow Rate

500 nL / min

Chromatograms

Data source: Panorama

Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | y9 (1+) | 14.8 | 8.9 | 5.8 | 23.7 | 20.3 | 23.4 | 27.9 | 22.2 | 24.1 | 25 | 15 | 15 | | y8 (1+) | 13.6 | 6.8 | 8.4 | 18.1 | 18.9 | 25.8 | 22.6 | 20.1 | 27.1 | 25 | 15 | 15 | | y7 (1+) | 10.6 | 7.3 | 8.1 | 20.4 | 24.4 | 23.3 | 23 | 25.5 | 24.7 | 25 | 15 | 15 | | sum | 8.9 | 6.6 | 7.4 | 17.2 | 20.9 | 23.7 | 19.4 | 21.9 | 24.8 | 25 | 15 | 15 |

Additional Resources and Comments

Assay Details for CPTAC-372 Collapse assay details

Data source: Panorama

Official Gene Symbol

FASN

Peptide Sequence

EDGLAQQQTQLNLR

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

2207

Peptide End

2220

CPTAC ID

CPTAC-372

Peptide Molecular Mass

1,612.8169

Species

Homo sapiens (Human)

Assay Type

Direct MRM

Matrix

cell line lysate pool

Submitting Laboratory

Broad Institute and FHCRC

Submitting Lab PI

Steve Carr

Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253

Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.

Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

5500 QTRAP (ABSCIEX)

Internal Standard

peptide

Peptide Standard Purity

>95%

Peptide Standard Label Type

13C,15N

LC

nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)

Column Packing

ChromXP C18-CL, 3 um, 120A

Column Dimensions

150 x 0.075 mm

Flow Rate

500 nL / min

Chromatograms

Data source: Panorama

Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | y9 (1+) | 6.9 | 5.8 | 3 | 13.4 | 18.9 | 4.5 | 15.1 | 19.8 | 5.4 | 15 | 25 | 15 | | y8 (1+) | 6.7 | 5.1 | 4.8 | 8.1 | 17.9 | 4.8 | 10.5 | 18.6 | 6.8 | 15 | 25 | 15 | | y7 (1+) | 5.7 | 4.9 | 4.7 | 9 | 18.4 | 7.1 | 10.7 | 19 | 8.5 | 15 | 25 | 15 | | sum | 5.3 | 4.6 | 3.9 | 8.4 | 18.1 | 4.7 | 9.9 | 18.7 | 6.1 | 15 | 25 | 15 |

Additional Resources and Comments

Assay Details for CPTAC-369 Collapse assay details

Data source: Panorama

Official Gene Symbol

FASN

Peptide Sequence

FDASFFGVHPK

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

60

Peptide End

70

CPTAC ID

CPTAC-369

Peptide Molecular Mass

1,250.6084

Species

Homo sapiens (Human)

Assay Type

Direct MRM

Matrix

cell line lysate pool

Submitting Laboratory

Broad Institute and FHCRC

Submitting Lab PI

Steve Carr

Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253

Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.

Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

5500 QTRAP (ABSCIEX)

Internal Standard

peptide

Peptide Standard Purity

>95%

Peptide Standard Label Type

13C,15N

LC

nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)

Column Packing

ChromXP C18-CL, 3 um, 120A

Column Dimensions

150 x 0.075 mm

Flow Rate

500 nL / min

Chromatograms

Data source: Panorama

Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | y6 (1+) | 31.8 | 19 | 15 | 63.5 | 24.7 | 69.4 | 71 | 31.2 | 71 | 25 | 15 | 15 | | y5 (1+) | 5.9 | 5.4 | 4.2 | 12.2 | 7.1 | 13.8 | 13.6 | 8.9 | 14.4 | 25 | 15 | 15 | | y9 (2+) | 8.2 | 6.5 | 5.5 | 15.8 | 11.7 | 20.2 | 17.8 | 13.4 | 20.9 | 25 | 15 | 15 | | sum | 8.3 | 4.6 | 4.2 | 16 | 7.8 | 22.8 | 18 | 9.1 | 23.2 | 25 | 15 | 15 |

Additional Resources and Comments

Assay Details for CPTAC-370 Collapse assay details

Data source: Panorama

Official Gene Symbol

FASN

Peptide Sequence

LQVVDQPLPVR

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

374

Peptide End

384

CPTAC ID

CPTAC-370

Peptide Molecular Mass

1,262.7347

Species

Homo sapiens (Human)

Assay Type

Direct MRM

Matrix

cell line lysate pool

Submitting Laboratory

Broad Institute and FHCRC

Submitting Lab PI

Steve Carr

Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253

Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.

Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

5500 QTRAP (ABSCIEX)

Internal Standard

peptide

Peptide Standard Purity

>95%

Peptide Standard Label Type

13C,15N

LC

nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)

Column Packing

ChromXP C18-CL, 3 um, 120A

Column Dimensions

150 x 0.075 mm

Flow Rate

500 nL / min

Chromatograms

Data source: Panorama

Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | y8 (1+) | 7.5 | 4.8 | 4.3 | 7.3 | 5.5 | 4.1 | 10.5 | 7.3 | 5.9 | 15 | 25 | 15 | | y7 (1+) | 8.7 | 4.5 | 3.1 | 11.5 | 5.5 | 4.2 | 14.4 | 7.1 | 5.2 | 15 | 25 | 15 | | y6 (1+) | 23 | 4.9 | 2.1 | 22.9 | 5.5 | 3.6 | 32.5 | 7.4 | 4.2 | 15 | 25 | 15 | | sum | 5.4 | 4 | 2.6 | 6.4 | 4.9 | 2.2 | 8.4 | 6.3 | 3.4 | 15 | 25 | 15 |

Additional Resources and Comments

Assay Details for non-CPTAC-3808 Collapse assay details

Data source: Panorama

Official Gene Symbol

Fasn

Peptide Sequence

VAEVLAGEGHLYSR

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

1237

Peptide End

1250

CPTAC ID

non-CPTAC-3808

Peptide Molecular Mass

1,499.7732

Species

Mus musculus (Mouse)

Assay Type

Direct MRM

Matrix

Plasma

Submitting Laboratory

UVic-Genome BC Proteomics Centre

Submitting Lab PI

Christoph Borchers

Publication

View Details (opens in a new window)

Molecular phenotyping of laboratory mouse strains using 500 multiple reaction monitoring mass spectrometry plasma assays. Michaud SA, Sinclair NJ, Petrošová H, Palmer AL, Pistawka AJ, Zhang S, Hardie DB, Mohammed Y Eshghi A1, Richard VR, Sickmann A, Borchers CH. Commun Biol. 2018 Jun 27;1:78. doi: 10.1038/s42003-018-0087-6. eCollection 2018.

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

Agilent 6490/6495 QQQ

Internal Standard

synthetic peptide

Peptide Standard Purity

>80%

Peptide Standard Label Type

13C and 15N at C-terminus R

LC

1290 LC (Agilent)

Column Packing

Zorbax Eclipse Plus C18, 1.8 µm

Column Dimensions

2.1 x 150 mm

Flow Rate

400 µL/min

Chromatograms

Data source: Panorama

Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | y12 (2+) | 9.7 | 9.1 | 5.8 | 10.4 | 16.5 | 6.9 | 14.2 | 18.8 | 9 | 15 | 15 | 15 | | y10 (2+) | 7.7 | 10.7 | 6.7 | 9.6 | 12.4 | 7.5 | 12.3 | 16.4 | 10.1 | 15 | 15 | 15 | | y9 (2+) | 21.4 | 9.3 | 16.9 | 39.6 | 19.9 | 32.9 | 45 | 22 | 37 | 15 | 15 | 15 | | y12 (3+) | 44.6 | 19.7 | 33.4 | 61.8 | 27.9 | 42.6 | 76.2 | 34.2 | 54.1 | 15 | 15 | 15 | | y7 (3+) | 57.2 | 20.2 | 11.8 | 80.7 | 26.4 | 24.4 | 98.9 | 33.2 | 27.1 | 15 | 15 | 15 | | sum | 7.5 | 5.2 | 7.2 | 13.7 | 9.2 | 14.4 | 15.6 | 10.6 | 16.1 | 15 | 15 | 15 |

Additional Resources and Comments